Blog
156 Articles
A Very Lucky Man
Dr. John Heller knew enough about pancreatic cancer to know that a clinical trial was a great option for a stage IV patient.
Let’s Talk About Rasonque: a Q&A for Our Community
Do you have questions about the newly approved drug Rasonque, generic name daraxonrasib? You can find all the answers on this page.
A New Approach to MEK Inhibition for First-Line Treatment
Dr. Eileen O’Reilly outlines a phase III trial of a targeted therapy for patients with metastatic pancreatic cancer.
The FDA Approves Rasonque™ (Daraxonrasib)
The FDA has approved Rasonque (daraxonrasib), the first drug approved to target KRAS in pancreatic cancer patients.
Daraxonrasib: What To Know About Common Side Effects
Oncodermatologist Dr. Ian Tattersall discusses the rash caused by the new KRAS drug daraxonrasib, and best options to manage the rash.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.
From Dismissal to Diagnosis
Elizabeth Rountree’s first doctor dismissed her symptoms of itchiness and abdominal discomfort, but her gastroenterologist listened and ordered important tests.
Large Clinical Trial For Cachexia Treatment
Lead investigator Dr. Jeffrey Crawford reports on the positive results from a cachexia clinical trial of a new immunotherapy drug to treat the condition.
(Currently) Incurable, (Continuously) Fighting
Katie DeCarlo is continuously fighting her PNET. She is determined to try and will continue to try as many types of treatment as possible
FDA Approves Tumor Treating Fields For Locally Advanced Disease
Dr. Vincent Picozzi explains how the recently approved tumor treating fields device is changing the game for pancreatic cancer patients.
Pancreatic Cancer at Any Age
Long-term survivor Ryan Dwars was diagnosed at age 36, with young children, but he has been determined to be an outlier.
Novel Oral Drug Shows Promise
Dr. Barbara Ma provides context for the nine-month data on a clinical trial of the novel drug atebimetinib and standard chemo.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.